{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '84', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'If a participant withdraws from the study, they will no longer receive study intervention or be', 'followed at scheduled protocol visits.', 'Specific details regarding procedures to be performed at the time of withdrawal from the', 'study are outlined in Section 8.1.9. The procedures to be performed should a participant', 'repeatedly fail to return for scheduled visits and/or if the study site is unable to contact the', 'participant are outlined in Section 7.3.', '7.3', 'Lost to Follow-up', 'If a participant fails to return to the clinic for a required study visit and/or if the site is unable', 'to contact the participant, the following procedures are to be performed:', 'The site must attempt to contact the participant and reschedule the missed visit. If the', 'participant is contacted, the participant should be counseled on the importance of', 'maintaining the protocol-specified visit schedule.', 'The investigator or designee must make every effort to regain contact with the', 'participant at each missed visit (eg, telephone calls and/or a certified letter to the', \"participant's last known mailing address or locally equivalent methods). These\", \"contact attempts should be documented in the participant's medical record.\", 'Note: A participant is not considered lost to follow-up until the last scheduled visit for', 'the individual participant. The missing data for the participant will be managed via', 'the prespecified statistical data handling and analysis guidelines.', '8', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA.', 'Adherence to the study design requirements, including those specified in the SoA, is', 'essential and required for study conduct.', 'The investigator is responsible for ensuring that procedures are conducted by', 'appropriately qualified or trained staff. Delegation of study site personnel', 'responsibilities will be documented in the Investigator Trial File Binder (or', 'equivalent).', 'All study-related medical decisions must be made by an investigator who is a', 'qualified physician.', 'All screening evaluations must be completed and reviewed to confirm that potential', 'participants meet all eligibility criteria. The investigator will maintain a screening log', 'to record details of all participants screened and to confirm eligibility or record', 'reasons for screening failure, as applicable.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '85', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', \"Procedures conducted as part of the participant's routine clinical management (eg,\", 'blood count) and obtained before signing of ICF may be utilized for screening or', 'baseline purposes provided the procedure met the protocol-specified criteria and were', 'performed within the time frame defined in the SoA.', 'Additional evaluations/testing may be deemed necessary by the investigator and or', 'the Sponsor for reasons related to participant safety. In some cases, such', 'evaluation/testing may be potentially sensitive in nature (eg, HIV, hepatitis C), and', 'thus local regulations may require that additional informed consent be obtained from', 'the participant. In these cases, such evaluations/testing will be performed in', 'accordance with those regulations.', 'Repeat or unscheduled samples may be taken for safety reasons or for technical issues with', 'the samples.', '8.1', 'Administrative and General Procedures', '8.1.1', 'Informed Consent', 'The investigator or medically qualified designee (consistent with local requirements) must', 'obtain documented informed consent from each potential participant or their legally', 'acceptable representative prior to participating in this clinical study or future biomedical', \"research. If there are changes to the participant's status during the study (eg, health or age of\", 'majority requirements), the investigator or medically qualified designee must ensure the', 'appropriate documented informed consent is in place.', '8.1.1.1', 'General Informed Consent', 'Informed consent given by the participant or their legally acceptable representative must be', 'documented on a consent form. The form must include the trial protocol number, trial', 'protocol title, dated signature, and /agreement of the participant (or his/her legally acceptable', 'representative) and of the person conducting the consent discussion.', 'A copy of the signed and dated informed consent form should be given to the participant (or', 'their legally acceptable representative) before participation in the study.', 'The initial ICF, any subsequent revised written ICF, and any written information provided to', \"the participant must receive the IRB/IEC's approval/favorable opinion in advance of use. The\", 'participant or his/her legally acceptable representative should be informed in a timely manner', \"if new information becomes available that may be relevant to the participant's willingness to\", 'continue participation in the study. The communication of this information will be provided', 'and documented via a revised consent form or addendum to the original consent form that', \"captures the participant's or the participant's legally acceptable representative's dated\", 'signature.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}